COMMUNIQUÉS West-GlobeNewswire

HealthLynked Launches AI-Powered Healthcare Communication Platform Featuring 24/7 Appointment Scheduling and Medical Office AI Agents
29/06/2026
NAPLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK ), a leader in healthcare technology, patient engagement, and care coordination, today announced the launch of its next- [...]
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
29/06/2026
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics [...]
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
29/06/2026
Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of molecular diagnostic [...]
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
29/06/2026
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial [...]
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
29/06/2026
Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Acentra Health Executives Meghan Harris and Verlon Johnson Recognized on Becker’s Healthcare’s 2026 Women in Health IT to Know List
29/06/2026
National recognition underscores Acentra Health leaders' demonstrated impact in advancing healthcare technology, innovation, and improved outcomes across the healthcare ecosystem MCLEAN, Va., June 29, 2026 (GLOBE [...]
Tria Federal Earns Three Positions on NASA SEWP VI Government-Wide IT Contract
29/06/2026
Awards position Tria and its joint ventures to serve federal health and public safety agencies across the full spectrum of IT and enterprise technology needs ARLINGTON, Va., June 29, 2026 (GLOBE NEWSWIRE) -- Tria [...]
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
29/06/2026
Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period Data presented at the 6th World Congress of Cutaneous Lymphomas meeting in Montreal, Canada [...]
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
29/06/2026
Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle ™ Technology for Hydrophobic Therapeutics SAN DIEGO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Oncotelic [...]
Novo Nordisk A/S - share repurchase programme
29/06/2026
Bagsværd, Denmark, 29 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
29/06/2026
June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage [...]
George Medicines appoints Brendan Walsh as Senior Vice President of Supply Chain & Technical Operations
29/06/2026
Brendan Walsh brings more than 20 years of operational leadership to support George Medicines’ global commercial expansion of GMRx2 London, UK, Boston, MA, 29 June 2026 – George Medicines, a late-stage biopharmaceutical [...]
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
29/06/2026
HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults with MDD Primary [...]
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
29/06/2026
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
29/06/2026
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
29/06/2026
- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1 , 2 ,3 , EMBRACE, for potential U.S. FDA [...]
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
29/06/2026
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted Breakthrough Therapy [...]
Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement
29/06/2026
Oslo, 29 June 2026 : Reference is made to the stock exchange announcement by Zelluna ASA (the "Company") on 18 June 2026 regarding completion of a private placement of 3,143,958 new shares at a subscription price of NOK [...]
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
29/06/2026
Company expands executive team with strategic corporate affairs leader as it advances its differentiated obesity portfolio WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage [...]

Pages